Company intelligence / Profile preview

Coral Genomics

San Francisco, California, United Statescdhc.noaa.gov ↗

Ownership: Private
Development stage: Other

Overview

Coral Genomics developed a genomics-driven platform integrating genetic, molecular, functional, and clinical data to help healthcare providers predict patient responses to drugs. The company focused on improving the efficiency of drug development—especially in autoimmune diseases—by enabling better patient stratification for clinical trials. It created large datasets representing diverse human biology to enhance personalized healthcare solutions. The company appears to be closed as of the latest available information.

Therapeutic areas: ImmunologyGastroenterologyOther
Modalities: Clinical test (for drug response prediction)Data platform (genomic data integration)
Industry: Molecular Diagnostics

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Coral Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coral Genomics.

Explore the full profile